Q-omics provides the consensus-scored CHIC1 profile across patient tissues and cancer cell-line models. CHIC1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHIC1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CHIC1 RNA expression shows 20,222 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where CHIC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHIC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHIC1 survival associations across molecular data types. CHIC1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHIC1 RNA expression–survival associations across cancer types. High CHIC1 expression shows unfavorable associations in UVM and LAML, but favorable associations in KIRC, ACC, SKCM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHIC1 RNA expression.
This table summarizes CHIC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CHIC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHIC1 shows lower tumor expression in BLCA, THCA, UCEC and LUSC and higher tumor expression in HNSC and CHOL. The BLCA box plot shows higher CHIC1 RNA expression in normal versus tumor tissue (log2 FC = −1.082, t-test p < 0.001).
This table shows molecular features associated with CHIC1 in patient tissues and cancer cell lines. In patient samples, CHIC1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHIC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
